GleamWall
中文EN

LEGN Legend Biotech Corp IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1801198 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY64.0%
TTM net income YoY-67.7%
TTM EPS YoY-68.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin61.4%
Operating margin—
Net margin-28.8%
FCF margin-12.5%
EBITDA margin—

Returns

ROE-29.1%
ROA-17.4%
ROIC (approx.)—
Asset turnover0.60x

Leverage & solvency

Liabilities / assets42.2%
Debt / equity0.32x
Current ratio1.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.34x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY20242024-12-31
Income statement
Revenue$1.03B$627.30M
Cost of revenue$397.10M$216.40M
Gross profit$631.80M$410.90M
R&D expense$414.70M$413.50M
Operating income-$136.50M-$309.50M
Interest expense$21.40M$21.60M
Pretax income-$282.60M-$158.10M
Income tax$14.20M$18.90M
Net income-$296.80M-$177.03M
EPS (basic)-0.81-0.48
EPS (diluted)-0.81-0.48
Weighted avg. shares (diluted)368.64M365.70M
Balance sheet
Cash & equivalents$901.90M$286.70M
Receivables$13.10M$6.40M
Inventory$32.00M$23.90M
Current assets$1.25B$1.28B
PP&E, netmay include right-of-use assets (IFRS)$116.30M$99.30M
Intangibles$1.90M$2.20M
Total assets$1.73B$1.67B
Current liabilities$636.40M$277.70M
Short-term debt$319.10M$0
Long-term debt$0$301.20M
Total debt$319.10M$301.20M
Total liabilities$731.60M$629.60M
Shareholders' equity$1.00B$1.04B
Net debt-$582.80M$14.50M
Cash flow statement
Operating cash flow-$100.20M-$144.00M
Capital expenditure$28.60M$14.10M
Free cash flow-$128.80M-$158.10M
Investing cash flow$709.60M-$850.60M
Financing cash flow-$300,000$5.70M
Stock-based compensation$64.60M$68.90M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.